Entity
Process
IFN-beta
--
G010228
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m93217
10
infinite
0
TRANSFAC | G010228 |
--
IL-6
--
G010262
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m93248
10
infinite
0
TRANSFAC | G010262 |
--
TNF-alpha
--
G010329
cso30:c:mRNA
cso30:i:CC_CellComponent
--
csml-variable:Double
m93309
10
infinite
0
TRANSFAC | G010329 |
--
IFN-gamma
--
G010453
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m93423
10
infinite
0
TRANSFAC | G010453 |
--
NF-kappaB {activated}
--
MO000000058
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m6
10
infinite
0
TRANSPATH | MO000000058 |
--
TRAF6
--
MO000000212
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m183
10
infinite
0
InterPro | IPR001841 |
TRANSPATH | MO000000212 |
--
IRAK-1
--
MO000000213
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m184
10
infinite
0
InterPro | IPR000719 |
TRANSPATH | MO000000213 |
--
IL-1
--
MO000000214
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m185
10
infinite
0
TRANSPATH | MO000000214 |
--
chemokines
--
MO000000265
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m211
10
infinite
0
TRANSPATH | MO000000265 |
--
TNF-alpha
--
MO000000289
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m230
10
infinite
0
InterPro | IPR003636 |
TRANSPATH | MO000000289 |
--
IL-6
--
MO000007384
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m871
10
infinite
0
InterPro | IPR003573 |
TRANSPATH | MO000007384 |
--
IRF-5
--
MO000007700
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m979
10
infinite
0
InterPro | IPR008984 |
TRANSPATH | MO000007700 |
--
IRF-7
--
MO000007702
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m980
10
infinite
0
TRANSPATH | MO000007702 |
--
MyD88
--
MO000016573
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1572
10
infinite
0
InterPro | IPR000157 |
TRANSPATH | MO000016573 |
--
IFNbeta
--
MO000016660
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1636
10
infinite
0
InterPro | IPR000471 |
TRANSPATH | MO000016660 |
--
IFNgamma
--
MO000016665
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1639
10
infinite
0
InterPro | IPR002069 |
TRANSPATH | MO000016665 |
--
calcineurin
--
MO000016724
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m1676
10
infinite
0
TRANSPATH | MO000016724 |
--
TRAF3
--
MO000016963
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1872
10
infinite
0
InterPro | IPR001841 |
TRANSPATH | MO000016963 |
--
Bcl-xL
--
MO000017151
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m2028
10
infinite
0
InterPro | IPR004725 |
TRANSPATH | MO000017151 |
--
IL-10
--
MO000017247
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m2103
10
infinite
0
InterPro | IPR000098 |
TRANSPATH | MO000017247 |
--
IL-8
--
MO000017264
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m2120
10
infinite
0
InterPro | IPR002473 |
TRANSPATH | MO000017264 |
--
PKCtheta
--
MO000017433
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m2259
10
infinite
0
InterPro | IPR000719 |
TRANSPATH | MO000017433 |
--
PLCgamma1
--
MO000017617
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m2395
10
infinite
0
InterPro | IPR001452 |
TRANSPATH | MO000017617 |
--
PLCgamma2
--
MO000017704
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m2464
10
infinite
0
InterPro | IPR001452 |
TRANSPATH | MO000017704 |
--
cytokines
--
MO000019387
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m3957
10
infinite
0
TRANSPATH | MO000019387 |
--
csml-variable:Double
m6433
10
infinite
0
--
flagellin
--
MO000022185
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m6485
10
infinite
0
TRANSPATH | MO000022185 |
--
TIRAP
--
MO000022528
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m6810
10
infinite
0
InterPro | IPR000157 |
TRANSPATH | MO000022528 |
--
IRAK-4
--
MO000039077
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m17258
10
infinite
0
TRANSPATH | MO000039077 |
--
--
e1
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane
--
--
--
csml-variable:Double
m1
0
infinite
0
--
--
e10
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytosol
--
--
--
csml-variable:Double
m10
0
infinite
0
--
Ca
--
e100
cso30:c:SmallMolecule
cso30:i:CC_Cytosol
--
csml-variable:Double
m104
0
infinite
0
--
cyclosporine
--
e101
cso30:c:SmallMolecule
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m105
0
infinite
0
--
FK506
--
e102
cso30:c:SmallMolecule
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m106
0
infinite
0
--
IkappaB: NFkappaB
--
e103
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m107
0
infinite
0
--
Triacyl lipopeptide
--
e104
cso30:c:SmallMolecule
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m108
0
infinite
0
--
Diacyl lipopeptide
--
e105
cso30:c:SmallMolecule
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m109
0
infinite
0
--
IkappaB {p}: NFkappaB
--
e106
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m110
0
infinite
0
--
IkappaB {ub}: NFkappaB
--
e107
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m111
0
infinite
0
--
--
e11
cso30:c:EntityBiologicalCompartment
cso30:i:CC_EndosomeLumen
--
--
--
csml-variable:Double
m12
0
infinite
0
--
--
e12
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Endosome
--
--
--
csml-variable:Double
m13
0
infinite
0
--
Uev1A
--
e13
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m14
0
infinite
0
--
TLR ligand
--
e14
cso30:c:Protein
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m16
0
infinite
0
--
TLR ligand: TLR
--
e15
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m17
0
infinite
0
--
TLR ligand: TLR: MyD88
--
e16
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m18
0
infinite
0
--
IL1
--
e17
cso30:c:mRNA
cso30:i:CC_CellComponent
--
csml-variable:Double
m19
10
infinite
0
TRANSFAC | G011140 |
--
csml-variable:Double
m22
0
infinite
0
--
--
e2
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m2
0
infinite
0
--
TLR2: TLR1: Triacyl lipopeptide
--
e21
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m25
0
infinite
0
--
TLR2: TLR6: Diacyl lipopeptide
--
e22
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m26
0
infinite
0
--
TLR2: TLR6: Diacyl lipopeptide: TIRAP
--
e23
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m27
0
infinite
0
--
TLR2: TLR1: Triacyl lipopeptide: TIRAP
--
e24
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
csml-variable:Double
m28
0
infinite
0
--
TLR2: TLR1: Triacyl lipopeptide: TIRAP: MyD88
--
e25
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m29
0
infinite
0
--
TLR2: TLR6:Diacyl lipopeptide: TIRAP: MyD88
--
e26
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m30
0
infinite
0
--
csml-variable:Double
m31
0
infinite
0
--
R-848: TLR7
--
e28
cso30:c:Complex
cso30:i:CC_EndosomeLumen
--
csml-variable:Double
m32
0
infinite
0
--
R-848: TLR8
--
e29
cso30:c:Complex
cso30:i:CC_EndosomeMembrane
--
csml-variable:Double
m33
0
infinite
0
--
--
e3
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
--
csml-variable:Double
m3
0
infinite
0
--
CpG DNA: TLR9
--
e30
cso30:c:Complex
cso30:i:CC_EndosomeLumen
--
csml-variable:Double
m34
0
infinite
0
--
flagellin: TLR5
--
e31
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m35
0
infinite
0
--
csml-variable:Double
m36
10
infinite
0
Affymetrix | 1369_s_at |
Ensembl | ENSG00000169429 |
HGNC | IL8 |
OMIM | 146930 |
Proteome | HumanPSD/IL8 |
RefSeq | NM_000584 |
TRANSFAC | G000317 |
Unigene | Hs.551925 |
--
flagellin: TLR5: MyD88
--
e33
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m37
0
infinite
0
--
R-848: TLR7: MyD88
--
e34
cso30:c:Complex
cso30:i:CC_EndosomeMembrane
--
csml-variable:Double
m38
0
infinite
0
--
R-848: TLR8: MyD88
--
e35
cso30:c:Complex
cso30:i:CC_EndosomeLumen
--
csml-variable:Double
m39
0
infinite
0
--
CpG DNA: TLR9: MyD88
--
e36
cso30:c:Complex
cso30:i:CC_EndosomeLumen
--
csml-variable:Double
m40
0
infinite
0
--
R-848: TLR8: MyD88: IRAK-1: IRAK-4: TRAF6: TRAF3: IRF-5: IRF-7
--
e37
cso30:c:Complex
cso30:i:CC_EndosomeLumen
--
csml-variable:Double
m41
0
infinite
0
--
R-848: TLR7: MyD88: IRAK-1: IRAK-4: TRAF6: TRAF3: IRF-5: IRF-7
--
e38
cso30:c:Complex
cso30:i:CC_EndosomeMembrane
--
csml-variable:Double
m42
0
infinite
0
--
CpG DNA: TLR9: MyD88: IRAK-1: IRAK-4: TRAF6: TRAF3: IRF-5: IRF-7
--
e39
cso30:c:Complex
cso30:i:CC_EndosomeMembrane
--
csml-variable:Double
m43
0
infinite
0
--
--
e4
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m4
0
infinite
0
--
LPS: TLR4
--
e40
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m44
0
infinite
0
--
LPS: TLR4: TIRAP
--
e41
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m45
0
infinite
0
--
LPS: TLR4: TRAM
--
e42
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
csml-variable:Double
m46
0
infinite
0
--
LPS: TLR4: TIRAP: MyD88
--
e43
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m47
0
infinite
0
--
LPS: TLR4: TRAM: TRIF
--
e44
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m48
0
infinite
0
--
LPS: TLR4: TRAM: TRIF: RIP1
--
e45
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m49
0
infinite
0
--
poly I:C: TLR3
--
e46
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
csml-variable:Double
m63
0
infinite
0
--
poly I:C: TLR3: TRIF
--
e47
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m64
0
infinite
0
--
csml-variable:Double
m65
0
infinite
0
--
poly I:C: TLR3: TRIF: RIP1
--
e49
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m66
0
infinite
0
--
IKK-alpha:IKK-beta:IKK-gamma
--
e5
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m5
10
infinite
0
TRANSPATH | MO000016661 |
--
--
e50
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelopeLumen
--
--
--
csml-variable:Double
m50
0
infinite
0
--
--
e51
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearPore
--
--
--
csml-variable:Double
m51
0
infinite
0
--
--
e52
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearInnerMembrane
--
--
--
csml-variable:Double
m52
0
infinite
0
--
--
e53
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearLumen
--
--
--
csml-variable:Double
m53
0
infinite
0
--
--
e54
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearOuterMembrane
--
--
--
csml-variable:Double
m54
0
infinite
0
--
--
e55
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleus
--
--
--
csml-variable:Double
m55
0
infinite
0
--
--
e56
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleoplasm
--
--
--
csml-variable:Double
m56
0
infinite
0
--
--
e57
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearBody
--
--
--
csml-variable:Double
m57
0
infinite
0
--
--
e58
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleolus
--
--
--
csml-variable:Double
m58
0
infinite
0
--
--
e59
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelope
--
--
--
csml-variable:Double
m59
0
infinite
0
--
--
e6
cso30:c:EntityBiologicalCompartment
cso30:i:CC_EndosomeMembrane
--
--
--
csml-variable:Double
m11
0
infinite
0
--
--
e60
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Chromatin
--
--
--
csml-variable:Double
m60
0
infinite
0
--
--
e61
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearChromosome
--
--
--
csml-variable:Double
m61
0
infinite
0
--
--
e62
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearCentromere
--
--
--
csml-variable:Double
m62
0
infinite
0
--
TLR ligand: TLR: MyD88: IRAK-1: IRAK-4: TRAF6: IRF-5
--
e63
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m67
0
infinite
0
--
IRAK-1{p}: TRAF6
--
e64
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m68
0
infinite
0
--
TLR ligand: TLR: MyD88: IRAK-1{p}: IRAK-4: TRAF6: IRF-5
--
e65
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m70
0
infinite
0
--
TLR ligand: TLR: MyD88: IRAK-4: IRF-5
--
e66
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m71
0
infinite
0
--
IRAK-1{p}: TRAF6: TAK1: TAB1: TAB2: Ubc13: Uev1A
--
e67
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m72
0
infinite
0
--
IRAK-1{p}: TRAF6: TAK1 {activated}: TAB1: TAB2: Ubc13: Uev1A
--
e68
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m73
0
infinite
0
--
IKK-alpha:IKK-beta:IKK-gamma {p}
--
e69
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m74
0
infinite
0
--
--
e7
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell
--
--
--
csml-variable:Double
m7
0
infinite
0
--
MAPKs {activated}
--
e72
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m20
10
infinite
0
TRANSPATH | MO000000077 |
--
protein ramnents
--
e74
cso30:c:EntityBiological
cso30:i:CC_Cytosol
--
csml-variable:Double
m78
0
infinite
0
--
NF-kappaB {nucleus}
--
e75
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m79
10
infinite
0
TRANSPATH | MO000000058 |
--
TLR ligand: TLR: MyD88: IRAK-1: IRAK-4: TRAF6: IRF-5 {activated}
--
e76
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m80
0
infinite
0
--
IFNalpha
--
e77
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m81
10
infinite
0
InterPro | IPR000471 |
TRANSPATH | MO000016659 |
--
antigen-MHC complex
--
e78
cso30:c:Complex
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m82
0
infinite
0
--
IFNalpha
--
e79
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m83
10
infinite
0
TRANSFAC | G010227 |
--
--
e8
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell_WithoutCellWall_
--
--
--
csml-variable:Double
m8
0
infinite
0
--
antigen-MHC complex: TCR: CD3zeta
--
e80
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m84
0
infinite
0
--
TCR: CD3zeta
--
e81
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m85
0
infinite
0
--
antigen-MHC complex: TCR: CD3zeta {p}
--
e82
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m86
0
infinite
0
--
antigen-MHC complex: TCR: CD3zeta {p}: ZAP-70
--
e83
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
csml-variable:Double
m87
0
infinite
0
--
LAT: SLP-76
--
e84
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m88
0
infinite
0
--
LAT {p}: SLP-76 {p}
--
e85
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m89
0
infinite
0
--
LAT {p}: SLP-76 {p}: PLCgamma1
--
e86
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m90
0
infinite
0
--
PKCtheta {p}
--
e87
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m91
0
infinite
0
--
antigen-MHC complex: TCR: CD3zeta {p}: ZAP-70: IRAK-4
--
e88
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m92
0
infinite
0
--
calcineurin {activated}
--
e89
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m93
10
infinite
0
TRANSPATH | MO000016724 |
--
--
e9
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytoplasm
--
--
--
csml-variable:Double
m9
0
infinite
0
--
NF-AT {activated}
--
e90
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m94
10
infinite
0
TRANSPATH | MO000017212 |
--
csml-variable:Double
m95
0
infinite
0
--
CBM complex: PKCtheta {p}
--
e92
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m96
0
infinite
0
--
PMA: TCR
--
e93
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m97
0
infinite
0
--
PLCbeta {activated}
--
e94
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m98
10
infinite
0
TRANSPATH | MO000000133 |
--
PLCgamma2 {activated}
--
e95
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m99
10
infinite
0
InterPro | IPR001452 |
TRANSPATH | MO000017704 |
--
CD25
--
e96
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m100
0
infinite
0
--
Bcl-xL
--
e97
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m101
0
infinite
0
--
cytokines
--
e98
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m102
0
infinite
0
--
chemokines
--
e99
cso30:c:mRNA
cso30:i:CC_Nucleolus
--
--
csml-variable:Double
m103
0
infinite
0
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c1 : 1
stoichiometry:c2 : 1
stoichiometry:c3 : 1
m16*m3962*0.1
nodelay
--
0
PMID: 17046325 Following ligand stimulation, TLRs associate with adaptor proteins such as myeloid differentiation primary response gene (MyD)88 through interaction between the individual Toll and interleukin-1 receptor (TIR) domains.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c27 : 1
stoichiometry:c28 : 1
stoichiometry:c29 : 1
m1572*m27*0.1
nodelay
--
0
PMID: 17046325 After TLR1, TLR2 and/or TLR6 stimulation, TIR domain-containing adaptor protein (TIRAP) and MyD88 are recruited to TLRs.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c303 : 1
stoichiometry:c313 : 1
stoichiometry:c293 : 1
m19*m44*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c319 : 1
stoichiometry:c320 : 1
m90*0.1
nodelay
--
0
PMID: 17046325 LAT?SLP-76?PLCgamma1 induces Ca2+ mobilization, the activation of calcineurin and, finally, NF-AT activation (iv), whereas PKCtheta co-operates with the CBM complex to culminate in NF-kappaB activation.
p41
p102
cso30:i:ME_ProteasomeDegradation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c322 : 1
stoichiometry:c178 : 1
stoichiometry:c179 : 1
stoichiometry:c323 : 1
m96*m111*0.1
nodelay
--
0
PMID: 17046325 LAT?SLP-76?PLCgamma1 induces Ca2+ mobilization, the activation of calcineurin and, finally, NF-AT activation (iv), whereas PKC¦È co-operates with the CBM complex to culminate in NF-kappaB activation.
p11
p11
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c31 : 1
stoichiometry:c32 : 1
stoichiometry:c33 : 1
m31*m19940*0.1
nodelay
--
0
PMID: 17046325, 16034093 In the absence of antigen-presenting cells (APCs), flagellin (a TLR5 ligand) and R-848 (a TLR7 and/or TLR8 ligand) are synergized by suboptimal TCR-dependent or TCR-independent stimulation to enhance the proliferation and production of IFN-gamma, IL-8 and IL-10 by human CD4+ T cells.
p12
p12
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c34 : 1
stoichiometry:c35 : 1
stoichiometry:c36 : 1
m31*m19823*0.1
nodelay
--
0
PMID: 17046325, 16034093 In the absence of antigen-presenting cells (APCs), flagellin (a TLR5 ligand) and R-848 (a TLR7 and/or TLR8 ligand) are synergized by suboptimal TCR-dependent or TCR-independent stimulation to enhance the proliferation and production of IFN-gamma, IL-8 and IL-10 by human CD4+ T cells.
p13
p13
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c37 : 1
stoichiometry:c38 : 1
stoichiometry:c39 : 1
m19828*m22*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
p14
p14
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c40 : 1
stoichiometry:c41 : 1
stoichiometry:c42 : 1
m3966*m6485*0.1
nodelay
--
0
PMID: 17046325, 16034093 In the absence of antigen-presenting cells (APCs), flagellin (a TLR5 ligand) and R-848 (a TLR7 and/or TLR8 ligand) are synergized by suboptimal TCR-dependent or TCR-independent stimulation to enhance the proliferation and production of IFN-gamma, IL-8 and IL-10 by human CD4+ T cells.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c43 : 1
stoichiometry:c44 : 1
stoichiometry:c45 : 1
m1572*m35*0.1
nodelay
--
0
PMID: 17046325 Following TLR5 stimulation, MyD88 but not TIRAP is recruited into the receptor complex.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c46 : 1
stoichiometry:c48 : 1
stoichiometry:c49 : 1
m1572*m32*0.1
nodelay
--
0
PMID: 17046325 Following TLR7, TLR8 and/or TLR9 stimulation, a cytoplasmic signaling complex consisting of MyD88, IRAK-1, interferon regulatory factor (IRF)-5, IRF-7, TNF receptor-associated factor (TRAF)3, TRAF6 and IRAK-4 is formed.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c47 : 1
stoichiometry:c50 : 1
stoichiometry:c51 : 1
m1572*m33*0.1
nodelay
--
0
PMID: 17046325 Following TLR7, TLR8 and/or TLR9 stimulation, a cytoplasmic signaling complex consisting of MyD88, IRAK-1, interferon regulatory factor (IRF)-5, IRF-7, TNF receptor-associated factor (TRAF)3, TRAF6 and IRAK-4 is formed.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c52 : 1
stoichiometry:c53 : 1
stoichiometry:c54 : 1
m34*m1572*0.1
nodelay
--
0
PMID: 17046325 Following TLR7, TLR8 and/or TLR9 stimulation, a cytoplasmic signaling complex consisting of MyD88, IRAK-1, interferon regulatory factor (IRF)-5, IRF-7, TNF receptor-associated factor (TRAF)3, TRAF6 and IRAK-4 is formed.
p19
p19
cso30:i:ME_Binding
cso30:i:CC_EndosomeLumen
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c56 : 1
stoichiometry:c59 : 1
stoichiometry:c61 : 1
stoichiometry:c65 : 1
stoichiometry:c68 : 1
stoichiometry:c71 : 1
stoichiometry:c73 : 1
stoichiometry:c77 : 1
m184*m17258*m183*m979*m980*m1872*m38*0.1
nodelay
--
0
PMID: 17046325 Following TLR7, TLR8 and/or TLR9 stimulation, a cytoplasmic signaling complex consisting of MyD88, IRAK-1, interferon regulatory factor (IRF)-5, IRF-7, TNF receptor-associated factor (TRAF)3, TRAF6 and IRAK-4 is formed.
p2
p2
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c4 : 1
stoichiometry:c6 : 1
stoichiometry:c5 : 1
m1572*m17*0.1
nodelay
--
0
PMID: 17046325 Following ligand stimulation, TLRs associate with adaptor proteins such as myeloid differentiation primary response gene (MyD)88 through interaction between the individual Toll and interleukin-1 receptor (TIR) domains.
p20
p20
cso30:i:ME_Binding
cso30:i:CC_EndosomeLumen
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c55 : 1
stoichiometry:c58 : 1
stoichiometry:c62 : 1
stoichiometry:c64 : 1
stoichiometry:c67 : 1
stoichiometry:c70 : 1
stoichiometry:c74 : 1
stoichiometry:c76 : 1
m184*m17258*m183*m979*m980*m1872*m39*0.1
nodelay
--
0
PMID: 17046325 Following TLR7, TLR8 and/or TLR9 stimulation, a cytoplasmic signaling complex consisting of MyD88, IRAK-1, interferon regulatory factor (IRF)-5, IRF-7, TNF receptor-associated factor (TRAF)3, TRAF6 and IRAK-4 is formed.
p21
p21
cso30:i:ME_Binding
cso30:i:CC_EndosomeLumen
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c57 : 1
stoichiometry:c60 : 1
stoichiometry:c63 : 1
stoichiometry:c66 : 1
stoichiometry:c69 : 1
stoichiometry:c72 : 1
stoichiometry:c75 : 1
stoichiometry:c78 : 1
m184*m17258*m183*m979*m980*m1872*m40*0.1
nodelay
--
0
PMID: 17046325 Following TLR7, TLR8 and/or TLR9 stimulation, a cytoplasmic signaling complex consisting of MyD88, IRAK-1, interferon regulatory factor (IRF)-5, IRF-7, TNF receptor-associated factor (TRAF)3, TRAF6 and IRAK-4 is formed.
p22
p22
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c79 : 1
stoichiometry:c80 : 1
stoichiometry:c81 : 1
m155666*m3961*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c84 : 1
stoichiometry:c85 : 1
stoichiometry:c86 : 1
m44*m19005*0.1
nodelay
--
0
PMID: 17046325 However, after TLR4 stimulation, the TIR domain-containing adaptor protein inducing interferon ¦Â (TRIF)-related adaptor molecule (TRAM)?TRIF?RIP1 (receptor-interacting protein 1) signaling pathway is activated in addition to the TIRAP?MyD88 signaling pathway.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c83 : 1
stoichiometry:c88 : 1
stoichiometry:c82 : 1
m44*m6810*0.1
nodelay
--
0
PMID: 17046325 However, after TLR4 stimulation, the TIR domain-containing adaptor protein inducing interferon ¦Â (TRIF)-related adaptor molecule (TRAM)?TRIF?RIP1 (receptor-interacting protein 1) signaling pathway is activated in addition to the TIRAP?MyD88 signaling pathway.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c89 : 1
stoichiometry:c90 : 1
stoichiometry:c91 : 1
m45*m1572*0.1
nodelay
--
0
PMID: 17046325 However, after TLR4 stimulation, the TIR domain-containing adaptor protein inducing interferon ¦Â (TRIF)-related adaptor molecule (TRAM)?TRIF?RIP1 (receptor-interacting protein 1) signaling pathway is activated in addition to the TIRAP?MyD88 signaling pathway.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c87 : 1
stoichiometry:c92 : 1
stoichiometry:c93 : 1
m46*m18998*0.1
nodelay
--
0
PMID: 17046325 However, after TLR4 stimulation, the TIR domain-containing adaptor protein inducing interferon ¦Â (TRIF)-related adaptor molecule (TRAM)?TRIF?RIP1 (receptor-interacting protein 1) signaling pathway is activated in addition to the TIRAP?MyD88 signaling pathway.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c94 : 1
stoichiometry:c95 : 1
stoichiometry:c96 : 1
m15*m48*0.1
nodelay
--
0
PMID: 17046325 However, after TLR4 stimulation, the TIR domain-containing adaptor protein inducing interferon ¦Â (TRIF)-related adaptor molecule (TRAM)?TRIF?RIP1 (receptor-interacting protein 1) signaling pathway is activated in addition to the TIRAP?MyD88 signaling pathway.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c97 : 1
stoichiometry:c98 : 1
stoichiometry:c99 : 1
m3965*m65*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c100 : 1
stoichiometry:c101 : 1
stoichiometry:c102 : 1
m63*m18998*0.1
nodelay
--
0
PMID: 17046325 TLR3 signaling, only TRIF and RIP1 are recruited. The TRAM?TRIF?RIP1 signaling pathway is MyD88-independent but IRAK-4-dependent.
p3
p3
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c7 : 1
stoichiometry:c8 : 1
stoichiometry:c14 : 1
stoichiometry:c321 : 1
m3964*m3963*m108*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c103 : 1
stoichiometry:c104 : 1
stoichiometry:c105 : 1
m15*m64*0.1
nodelay
--
0
PMID: 17046325 TLR3 signaling, only TRIF and RIP1 are recruited. The TRAM?TRIF?RIP1 signaling pathway is MyD88-independent but IRAK-4-dependent.
p31
p31
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c106 : 1
stoichiometry:c107 : 1
stoichiometry:c108 : 1
stoichiometry:c109 : 1
stoichiometry:c205 : 1
stoichiometry:c110 : 1
m184*m17258*m979*m183*m18*0.1
nodelay
--
0
PMID: 17046325 IRAK-4, IRAK-1, IRF5 and TRAF6 are then recruited to the TLRs, which induces the association of IRAK-4 and MyD88 through their death domains. PMID: 17046325 Following TLR7, TLR8 and/or TLR9 stimulation, a cytoplasmic signaling complex consisting of MyD88, IRAK-1, interferon regulatory factor (IRF)-5, IRF-7, TNF receptor-associated factor (TRAF)3, TRAF6 and IRAK-4 is formed.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c111 : 1
stoichiometry:c112 : 1
m67*0.1
nodelay
--
0
PMID: 17046325 RAK-1 is phosphorylated by IRAK-4 and dissociates from the receptor together with TRAF6.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c113 : 1
stoichiometry:c114 : 1
stoichiometry:c115 : 1
m70*0.1
nodelay
--
0
PMID: 17046325 RAK-1 is phosphorylated by IRAK-4 and dissociates from the receptor together with TRAF6.
p34
p34
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c116 : 1
stoichiometry:c117 : 1
stoichiometry:c118 : 1
stoichiometry:c119 : 1
stoichiometry:c120 : 1
stoichiometry:c121 : 1
stoichiometry:c122 : 1
m68*m1573*m1583*m6433*m6443*m14*0.1
nodelay
--
0
PMID: 17046325 The released TRAF6 interacts with transforming growth factor (TGF)-beta-activated kinase (TAK)1, and TRAF6?TAK1 forms a large complex with E2 ubiquitin-conjugating enzyme (Ubc)13, ubiquitin-conjugating enzyme E2 variant 1 isoform A (Uev1A) and TAK1-binding protein (TAB)1?TAB2.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c123 : 1
stoichiometry:c124 : 1
m72*0.1
nodelay
--
0
PMID: 17046325 The released TRAF6 interacts with transforming growth factor (TGF)-beta-activated kinase (TAK)1, and TRAF6?TAK1 forms a large complex with E2 ubiquitin-conjugating enzyme (Ubc)13, ubiquitin-conjugating enzyme E2 variant 1 isoform A (Uev1A) and TAK1-binding protein (TAB)1?TAB2. PMID: 17046325 LAT?SLP-76?PLCgamma1 induces Ca2+ mobilization, the activation of calcineurin and, finally, NF-AT activation (iv), whereas PKC¦È co-operates with the CBM complex to culminate in NF-kappaB activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c125 : 1
stoichiometry:c126 : 1
stoichiometry:c127 : 1
m73*m5*0.1
nodelay
--
0
PMID: 17046325 Activated TAK1 phosphorylates and activates the IKK complex, consisting of IKK1, IKK2 and NEMO. PMID: 17046325 LAT?SLP-76?PLCgamma1 induces Ca2+ mobilization, the activation of calcineurin and, finally, NF-AT activation (iv), whereas PKC¦È co-operates with the CBM complex to culminate in NF-kappaB activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c130 : 1
stoichiometry:c128 : 1
stoichiometry:c129 : 1
m74*m107*0.1
nodelay
--
0
PMID: 17046325 The IKK complex induces IkappaB phosphorylation, which results in I¦ÊB ubiquitination and degradation. PMID: 17046325 LAT?SLP-76?PLCgamma1 induces Ca2+ mobilization, the activation of calcineurin and, finally, NF-AT activation (iv), whereas PKC¦È co-operates with the CBM complex to culminate in NF-kappaB activation.
p38
p38
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c131 : 1
stoichiometry:c136 : 1
stoichiometry:c132 : 1
m69*m73*0.1
nodelay
--
0
PMID: 17046325 Activated TAK1 also induces the activation of various stress kinases, including c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK).
p39
p39
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c133 : 1
stoichiometry:c135 : 1
stoichiometry:c134 : 1
m21*m73*0.1
nodelay
--
0
PMID: 17046325 Activated TAK1 also induces the activation of various stress kinases, including c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK).
p4
p4
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c10 : 1
stoichiometry:c11 : 1
stoichiometry:c16 : 1
stoichiometry:c9 : 1
m3964*m3987*m109*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c137 : 1
stoichiometry:c138 : 1
m110*0.1
nodelay
--
0
PMID: 17046325 The IKK complex induces IkappaB phosphorylation, which results in I¦ÊB ubiquitination and degradation. PMID: 17046325 LAT?SLP-76?PLCgamma1 induces Ca2+ mobilization, the activation of calcineurin and, finally, NF-AT activation (iv), whereas PKC¦È co-operates with the CBM complex to culminate in NF-kappaB activation.
p41
p41
cso30:i:ME_ProteasomeDegradation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c139 : 1
stoichiometry:c140 : 1
stoichiometry:c141 : 1
m111*0.1
nodelay
--
0
PMID: 17046325 The IKK complex induces IkappaB phosphorylation, which results in I¦ÊB ubiquitination and degradation. PMID: 17046325 IkappaB degradation liberates NF-kappaB and enables it to translocate into the nucleus where it can induce target gene expression. PMID: 17046325 LAT?SLP-76?PLCgamma1 induces Ca2+ mobilization, the activation of calcineurin and, finally, NF-AT activation (iv), whereas PKC¦È co-operates with the CBM complex to culminate in NF-kappaB activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c142 : 1
stoichiometry:c143 : 1
m6*0.1
nodelay
--
0
PMID: 17046325 IkappaB degradation liberates NF-kappaB and enables it to translocate into the nucleus where it can induce target gene expression.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c144 : 1
stoichiometry:c145 : 1
m67*0.1
nodelay
--
0
PMID: 17046325 Recently, it was revealed that IRF-5 interacts with, and is activated by, MyD88 and TRAF6, although it is unclear how IRAK-1, IRAK-4 and IRF-5 regulate TRAF6 dissociation from the receptor complex.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c147 : 1
stoichiometry:c149 : 1
stoichiometry:c148 : 1
m82*m85*0.1
nodelay
--
0
PMID: 17046325 In acquired immunity, the TCR recognizes a specific antigen?MHC complex on APCs. PMID: 17046325 TCR engagement results in the phosphorylation of TCR-associated CD3zeta chains by Lck and the recruitment of ZAP-70 to the phosphorylated CD3zeta chains, inducing phosphorylation of the adaptor proteins LAT and SLP-76.
p45
p45
cso30:i:ME_Phosphorylation
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c146 : 1
stoichiometry:c151 : 1
stoichiometry:c150 : 1
m84*m123*0.1
nodelay
--
0
PMID: 17046325 TCR engagement results in the phosphorylation of TCR-associated CD3zeta chains by Lck and the recruitment of ZAP-70 to the phosphorylated CD3zeta chains, inducing phosphorylation of the adaptor proteins LAT and SLP-76.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c152 : 1
stoichiometry:c153 : 1
stoichiometry:c154 : 1
m2529*m86*0.1
nodelay
--
0
PMID: 17046325 TCR engagement results in the phosphorylation of TCR-associated CD3zeta chains by Lck and the recruitment of ZAP-70 to the phosphorylated CD3zeta chains, inducing phosphorylation of the adaptor proteins LAT and SLP-76.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c159 : 1
stoichiometry:c155 : 1
stoichiometry:c156 : 1
m87*m88*0.1
nodelay
--
0
PMID: 17046325 TCR engagement results in the phosphorylation of TCR-associated CD3zeta chains by Lck and the recruitment of ZAP-70 to the phosphorylated CD3zeta chains, inducing phosphorylation of the adaptor proteins LAT and SLP-76. PMID: 17046325 PLC-gamma1 is recruited to the phosphorylated LAT?SLP-76 and generates Ins(1,4,5)P3.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c157 : 1
stoichiometry:c158 : 1
stoichiometry:c160 : 1
m89*m2395*0.1
nodelay
--
0
PMID: 17046325 PLC-gamma1 is recruited to the phosphorylated LAT?SLP-76 and generates Ins(1,4,5)P3.
p49
p49
cso30:i:ME_UnknownProduction
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c161 : 1
stoichiometry:c162 : 1
m90*0.1
nodelay
--
0
PMID: 17046325 PLC-gamma1 is recruited to the phosphorylated LAT?SLP-76 and generates Ins(1,4,5)P3.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c13 : 1
stoichiometry:c17 : 1
stoichiometry:c204 : 1
m30*m100*0.1
nodelay
--
0
PMID: 17046325, 16761317 Indeed, TLR2 induces co-stimulation in activated CD8+ T cells for proliferation and survival through the enhanced expression of CD25 and Bcl-xL.
p50
p50
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c163 : 1
stoichiometry:c168 : 1
stoichiometry:c186 : 1
stoichiometry:c187 : 1
stoichiometry:c164 : 1
m2259*m92*m2019*m2395*0.1
nodelay
--
0
PMID: 17046325 IRAK-4 affects only the phosphorylation of PKCtheta but not of CD3zeta, ZAP-70 or LAT. PMID: 17046325, 15802604 Although 3-phosphoinositide-dependent protein kinase (PDK)1 is responsible for activating PKCtheta and subsequent NF-kappaB activation after TCR stimulation , the association of IRAK-4 with PKCtheta or PDK1 was not observed. PMID: 17046325 It can be assumed that PKCbeta activation in B cells requires only PLC-gamma2 activation, whereas PKCtheta activation in T cells requires both PLC-gamma1 and IRAK-4.
p51
p51
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c165 : 1
stoichiometry:c166 : 1
stoichiometry:c167 : 1
m87*m17258*0.1
nodelay
--
0
PMID: 17046325 IRAK-4 constitutively associates with ZAP-70, and the assembled ZAP-70?IRAK-4 complex can be recruited to the TCR vicinity following stimulation.
p52
p52
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c169 : 1
stoichiometry:c171 : 1
stoichiometry:c170 : 1
m1676*m90*0.1
nodelay
--
0
PMID: 17046325 LAT?SLP-76?PLCgamma1 induces Ca2+ mobilization, the activation of calcineurin and, finally, NF-AT activation (iv), whereas PKCtheta co-operates with the CBM complex to culminate in NF-kappaB activation.
p53
p53
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c172 : 1
stoichiometry:c174 : 1
stoichiometry:c232 : 1
stoichiometry:c233 : 1
stoichiometry:c234 : 1
stoichiometry:c173 : 1
m2078*m93*m104*0.1
nodelay
--
0
PMID: 17046325 LAT?SLP-76?PLCgamma1 induces Ca2+ mobilization, the activation of calcineurin and, finally, NF-AT activation (iv), whereas PKCtheta co-operates with the CBM complex to culminate in NF-kappaB activation. PMID: 17046325 TCR signals could then have diversified into Ca2+-independent NF-kappaB activation and Ca2+-dependent NF-AT activation. PMID: 17046325 Cyclosporine A and FK506 specifically inhibit NF-AT activation in TCR signaling, and have been used for successful organ transplantation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c175 : 1
stoichiometry:c176 : 1
stoichiometry:c177 : 1
m91*m95*0.1
nodelay
--
0
PMID: 17046325 LAT?SLP-76?PLCgamma1 induces Ca2+ mobilization, the activation of calcineurin and, finally, NF-AT activation (iv), whereas PKC¦È co-operates with the CBM complex to culminate in NF-kappaB activation.
p56
p56
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c180 : 1
stoichiometry:c181 : 1
stoichiometry:c182 : 1
m2534*m117377*0.1
nodelay
--
0
PMID:17046325, 16574867, 11861617 Functional analyses demonstrated that IRAK-4-deficient T cells failed to respond to TCR stimulation but were able to respond to phorbol 12-myristate 13-acetate (PMA) stimulation [25] that directly activates protein kinase C (PKC)theta.
p57
p57
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c183 : 1
stoichiometry:c184 : 1
stoichiometry:c185 : 1
m97*m2259*0.1
nodelay
--
0
PMID:17046325, 16574867, 11861617 Functional analyses demonstrated that IRAK-4-deficient T cells failed to respond to TCR stimulation but were able to respond to phorbol 12-myristate 13-acetate (PMA) stimulation [25] that directly activates protein kinase C (PKC)theta.
p58
p58
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c188 : 1
stoichiometry:c189 : 1
m120*0.1
nodelay
--
0
PMID: 17046325 It can be assumed that PKCbeta activation in B cells requires only PLC-gamma2 activation, whereas PKCtheta activation in T cells requires both PLC-gamma1 and IRAK-4.
p59
p59
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c190 : 1
stoichiometry:c206 : 1
stoichiometry:c191 : 1
m2464*m98*0.1
nodelay
--
0
PMID: 17046325 It can be assumed that PKCbeta activation in B cells requires only PLC-gamma2 activation, whereas PKCtheta activation in T cells requires both PLC-gamma1 and IRAK-4.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c12 : 1
stoichiometry:c15 : 1
stoichiometry:c18 : 1
m30*m101*0.1
nodelay
--
0
PMID: 17046325, 16761317 Indeed, TLR2 induces co-stimulation in activated CD8+ T cells for proliferation and survival through the enhanced expression of CD25 and Bcl-xL.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c195 : 1
stoichiometry:c203 : 1
stoichiometry:c193 : 1
m100*m29*0.1
nodelay
--
0
PMID: 17046325, 16761317 Indeed, TLR2 induces co-stimulation in activated CD8+ T cells for proliferation and survival through the enhanced expression of CD25 and Bcl-xL.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c194 : 1
stoichiometry:c202 : 1
stoichiometry:c192 : 1
m101*m29*0.1
nodelay
--
0
PMID: 17046325, 16761317 Indeed, TLR2 induces co-stimulation in activated CD8+ T cells for proliferation and survival through the enhanced expression of CD25 and Bcl-xL.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c196 : 1
stoichiometry:c200 : 1
m36*0.1
nodelay
--
0
PMID: 17046325, 16034093 In the absence of antigen-presenting cells (APCs), flagellin (a TLR5 ligand) and R-848 (a TLR7 and/or TLR8 ligand) are synergized by suboptimal TCR-dependent or TCR-independent stimulation to enhance the proliferation and production of IFN-gamma, IL-8 and IL-10 by human CD4+ T cells.
p63
p63
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c197 : 1
stoichiometry:c221 : 1
stoichiometry:c201 : 1
m94230*m37*0.1
nodelay
--
0
PMID: 17046325, 16034093 In the absence of antigen-presenting cells (APCs), flagellin (a TLR5 ligand) and R-848 (a TLR7 and/or TLR8 ligand) are synergized by suboptimal TCR-dependent or TCR-independent stimulation to enhance the proliferation and production of IFN-gamma, IL-8 and IL-10 by human CD4+ T cells.
p64
p64
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c198 : 1
stoichiometry:c222 : 1
stoichiometry:c199 : 1
m93423*m41*0.1
nodelay
--
0
PMID: 17046325, 16034093 In the absence of antigen-presenting cells (APCs), flagellin (a TLR5 ligand) and R-848 (a TLR7 and/or TLR8 ligand) are synergized by suboptimal TCR-dependent or TCR-independent stimulation to enhance the proliferation and production of IFN-gamma, IL-8 and IL-10 by human CD4+ T cells.
p65
p65
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c207 : 1
stoichiometry:c219 : 1
stoichiometry:c217 : 1
m93423*m37*0.1
nodelay
--
0
PMID: 17046325, 16034093 In the absence of antigen-presenting cells (APCs), flagellin (a TLR5 ligand) and R-848 (a TLR7 and/or TLR8 ligand) are synergized by suboptimal TCR-dependent or TCR-independent stimulation to enhance the proliferation and production of IFN-gamma, IL-8 and IL-10 by human CD4+ T cells.
p66
p66
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c208 : 1
stoichiometry:c223 : 1
stoichiometry:c218 : 1
m93423*m42*0.1
nodelay
--
0
PMID: 17046325, 16034093 In the absence of antigen-presenting cells (APCs), flagellin (a TLR5 ligand) and R-848 (a TLR7 and/or TLR8 ligand) are synergized by suboptimal TCR-dependent or TCR-independent stimulation to enhance the proliferation and production of IFN-gamma, IL-8 and IL-10 by human CD4+ T cells.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c209 : 1
stoichiometry:c220 : 1
stoichiometry:c215 : 1
m36*m37*0.1
nodelay
--
0
PMID: 17046325, 16034093 In the absence of antigen-presenting cells (APCs), flagellin (a TLR5 ligand) and R-848 (a TLR7 and/or TLR8 ligand) are synergized by suboptimal TCR-dependent or TCR-independent stimulation to enhance the proliferation and production of IFN-gamma, IL-8 and IL-10 by human CD4+ T cells.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c210 : 1
stoichiometry:c216 : 1
m36*0.1
nodelay
--
0
PMID: 17046325, 16034093 In the absence of antigen-presenting cells (APCs), flagellin (a TLR5 ligand) and R-848 (a TLR7 and/or TLR8 ligand) are synergized by suboptimal TCR-dependent or TCR-independent stimulation to enhance the proliferation and production of IFN-gamma, IL-8 and IL-10 by human CD4+ T cells.
p69
p69
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c211 : 1
stoichiometry:c225 : 1
stoichiometry:c213 : 1
m94230*m41*0.1
nodelay
--
0
PMID: 17046325, 16034093 In the absence of antigen-presenting cells (APCs), flagellin (a TLR5 ligand) and R-848 (a TLR7 and/or TLR8 ligand) are synergized by suboptimal TCR-dependent or TCR-independent stimulation to enhance the proliferation and production of IFN-gamma, IL-8 and IL-10 by human CD4+ T cells.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c20 : 1
stoichiometry:c21 : 1
stoichiometry:c24 : 1
m6810*m26*0.1
nodelay
--
0
PMID: 17046325 After TLR1, TLR2 and/or TLR6 stimulation, TIR domain-containing adaptor protein (TIRAP) and MyD88 are recruited to TLRs.
p70
p70
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c212 : 1
stoichiometry:c224 : 1
stoichiometry:c214 : 1
m94230*m42*0.1
nodelay
--
0
PMID: 17046325, 16034093 In the absence of antigen-presenting cells (APCs), flagellin (a TLR5 ligand) and R-848 (a TLR7 and/or TLR8 ligand) are synergized by suboptimal TCR-dependent or TCR-independent stimulation to enhance the proliferation and production of IFN-gamma, IL-8 and IL-10 by human CD4+ T cells.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c228 : 1
stoichiometry:c230 : 1
stoichiometry:c226 : 1
m102*m67*0.1
nodelay
--
0
PMID: 17046325 Collectively, these studies demonstrated that some components from invading microorganisms stimulate TLRs on T cells directly, and enhance proliferation, cytokine and chemokine productions, and effector function.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c229 : 1
stoichiometry:c231 : 1
stoichiometry:c227 : 1
m103*m67*0.1
nodelay
--
0
PMID: 17046325 Collectively, these studies demonstrated that some components from invading microorganisms stimulate TLRs on T cells directly, and enhance proliferation, cytokine and chemokine productions, and effector function.
p73
p73
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c238 : 1
stoichiometry:c240 : 1
stoichiometry:c236 : 1
m93423*m44*0.1
nodelay
--
0
PMID: 17046325, 15229469 Only five TLRs ? TLR3, TLR4, TLR7, TLR8 and TLR9 ? produce IFNalpha, IFNbeta and IFNgamma as innate immune responses.
p74
p74
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c237 : 1
stoichiometry:c239 : 1
stoichiometry:c235 : 1
m93423*m66*0.1
nodelay
--
0
PMID: 17046325, 15229469 Only five TLRs ? TLR3, TLR4, TLR7, TLR8 and TLR9 ? produce IFNalpha, IFNbeta and IFNgamma as innate immune responses.
p75
p75
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c241 : 1
stoichiometry:c242 : 1
stoichiometry:c243 : 1
m43*m93423*0.1
nodelay
--
0
PMID: 17046325, 15229469 Only five TLRs ? TLR3, TLR4, TLR7, TLR8 and TLR9 ? produce IFNalpha, IFNbeta and IFNgamma as innate immune responses.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c249 : 1
stoichiometry:c266 : 1
stoichiometry:c244 : 1
m83*m43*0.1
nodelay
--
0
PMID: 17046325, 15229469 Only five TLRs ? TLR3, TLR4, TLR7, TLR8 and TLR9 ? produce IFNalpha, IFNbeta and IFNgamma as innate immune responses.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c250 : 1
stoichiometry:c268 : 1
stoichiometry:c245 : 1
m83*m41*0.1
nodelay
--
0
PMID: 17046325, 15229469 Only five TLRs ? TLR3, TLR4, TLR7, TLR8 and TLR9 ? produce IFNalpha, IFNbeta and IFNgamma as innate immune responses.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c251 : 1
stoichiometry:c270 : 1
stoichiometry:c246 : 1
m83*m42*0.1
nodelay
--
0
PMID: 17046325, 15229469 Only five TLRs ? TLR3, TLR4, TLR7, TLR8 and TLR9 ? produce IFNalpha, IFNbeta and IFNgamma as innate immune responses.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c252 : 1
stoichiometry:c272 : 1
stoichiometry:c247 : 1
m83*m66*0.1
nodelay
--
0
PMID: 17046325, 15229469 Only five TLRs ? TLR3, TLR4, TLR7, TLR8 and TLR9 ? produce IFNalpha, IFNbeta and IFNgamma as innate immune responses.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c19 : 1
stoichiometry:c22 : 1
stoichiometry:c23 : 1
m6810*m25*0.1
nodelay
--
0
PMID: 17046325 After TLR1, TLR2 and/or TLR6 stimulation, TIR domain-containing adaptor protein (TIRAP) and MyD88 are recruited to TLRs.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c253 : 1
stoichiometry:c264 : 1
stoichiometry:c248 : 1
m83*m44*0.1
nodelay
--
0
PMID: 17046325, 15229469 Only five TLRs ? TLR3, TLR4, TLR7, TLR8 and TLR9 ? produce IFNalpha, IFNbeta and IFNgamma as innate immune responses.
p81
p81
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c254 : 1
stoichiometry:c267 : 1
stoichiometry:c259 : 1
m93217*m43*0.1
nodelay
--
0
PMID: 17046325, 15229469 Only five TLRs ? TLR3, TLR4, TLR7, TLR8 and TLR9 ? produce IFNalpha, IFNbeta and IFNgamma as innate immune responses.
p82
p82
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c255 : 1
stoichiometry:c269 : 1
stoichiometry:c260 : 1
m93217*m41*0.1
nodelay
--
0
PMID: 17046325, 15229469 Only five TLRs ? TLR3, TLR4, TLR7, TLR8 and TLR9 ? produce IFNalpha, IFNbeta and IFNgamma as innate immune responses.
p83
p83
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c256 : 1
stoichiometry:c271 : 1
stoichiometry:c261 : 1
m93217*m42*0.1
nodelay
--
0
PMID: 17046325, 15229469 Only five TLRs ? TLR3, TLR4, TLR7, TLR8 and TLR9 ? produce IFNalpha, IFNbeta and IFNgamma as innate immune responses.
p84
p84
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c257 : 1
stoichiometry:c273 : 1
stoichiometry:c262 : 1
m93217*m66*0.1
nodelay
--
0
PMID: 17046325, 15229469 Only five TLRs ? TLR3, TLR4, TLR7, TLR8 and TLR9 ? produce IFNalpha, IFNbeta and IFNgamma as innate immune responses.
p85
p85
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c258 : 1
stoichiometry:c265 : 1
stoichiometry:c263 : 1
m93217*m44*0.1
nodelay
--
0
PMID: 17046325, 15229469 Only five TLRs ? TLR3, TLR4, TLR7, TLR8 and TLR9 ? produce IFNalpha, IFNbeta and IFNgamma as innate immune responses.
p86
p86
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c279 : 1
stoichiometry:c304 : 1
stoichiometry:c274 : 1
m93309*m30*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
p87
p87
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c280 : 1
stoichiometry:c307 : 1
stoichiometry:c275 : 1
m93309*m29*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
p88
p88
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c283 : 1
stoichiometry:c315 : 1
stoichiometry:c277 : 1
m93309*m44*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
p89
p89
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c281 : 1
stoichiometry:c310 : 1
stoichiometry:c276 : 1
m93309*m66*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c25 : 1
stoichiometry:c30 : 1
stoichiometry:c26 : 1
m1572*m28*0.1
nodelay
--
0
PMID: 17046325 After TLR1, TLR2 and/or TLR6 stimulation, TIR domain-containing adaptor protein (TIRAP) and MyD88 are recruited to TLRs.
p90
p90
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c282 : 1
stoichiometry:c318 : 1
stoichiometry:c278 : 1
m93309*m43*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
p91
p91
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c294 : 1
stoichiometry:c305 : 1
stoichiometry:c284 : 1
m93248*m30*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
p92
p92
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c295 : 1
stoichiometry:c308 : 1
stoichiometry:c285 : 1
m93248*m29*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
p93
p93
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c296 : 1
stoichiometry:c311 : 1
stoichiometry:c286 : 1
m93248*m66*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
p94
p94
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c297 : 1
stoichiometry:c316 : 1
stoichiometry:c287 : 1
m93248*m43*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
p95
p95
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c298 : 1
stoichiometry:c314 : 1
stoichiometry:c288 : 1
m93248*m44*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c299 : 1
stoichiometry:c306 : 1
stoichiometry:c289 : 1
m19*m30*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c300 : 1
stoichiometry:c309 : 1
stoichiometry:c290 : 1
m19*m29*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c301 : 1
stoichiometry:c312 : 1
stoichiometry:c291 : 1
m19*m66*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c302 : 1
stoichiometry:c317 : 1
stoichiometry:c292 : 1
m19*m43*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--